Trial Profile
A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination With AMG 479 in Subjects With Advanced, Refractory Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Conatumumab (Primary) ; Ganitumab (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Sarcoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen; ImmunityBio
- 01 Oct 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 06 Jan 2011 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Sep 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.